SELL and aggressive systemic mastocytosis: Of note, decreased cMo counts in ISM versus BMM were mostly at the expense of the CD62 L+ FcεRI+ subset (P = 0.011), while ASM cases showed higher counts of CD62L− FcεRI− cMo versus BMM (P = 0.047) (Figure 4B).